Investigational Drug Information for Alovudine
✉ Email this page to a colleague
What is the development status for investigational drug Alovudine?
Alovudine is an investigational drug.
There have been 8 clinical trials for Alovudine.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2004.
The most common disease conditions in clinical trials are HIV Infections, Acquired Immunodeficiency Syndrome, and Immunologic Deficiency Syndromes. The leading clinical trial sponsors are National Cancer Institute (NCI), Lederle Laboratories, and Boehringer Ingelheim.
Summary for Alovudine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 2,095 |
| WIPO Patent Applications | 922 |
| Japanese Patent Applications | 278 |
| Clinical Trial Progress | Phase 2 (2004-04-01) |
| Vendors | 43 |
Recent Clinical Trials for Alovudine
| Title | Sponsor | Phase |
|---|---|---|
| Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement | National Cancer Institute (NCI) | Phase 2 |
| Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy | National Cancer Institute (NCI) | Early Phase 1 |
Clinical Trial Summary for Alovudine
Top disease conditions for Alovudine
Top clinical trial sponsors for Alovudine
US Patents for Alovudine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
